These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A reappraisal of economic evaluation of pharmaceuticals. Science or marketing? Drummond MF Pharmacoeconomics; 1998 Jul; 14(1):1-9. PubMed ID: 10182189 [TBL] [Abstract][Full Text] [Related]
3. Pharmaceuticals and medical devices: business practices. Issue brief. Thomson Reuters/West Issue Brief Health Policy Track Serv; 2011 Jan; ():1-44. PubMed ID: 21374840 [No Abstract] [Full Text] [Related]
4. Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? O'Brien B Med Care; 1996 Dec; 34(12 Suppl):DS99-108. PubMed ID: 8969318 [No Abstract] [Full Text] [Related]
5. Evaluating the quality of published pharmacoeconomic evaluations. Sanchez LA Hosp Pharm; 1995 Feb; 30(2):146-8, 151-2. PubMed ID: 10140528 [No Abstract] [Full Text] [Related]
6. Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals. Luce BR Pharmacoeconomics; 1993 Jan; 3(1):1-9. PubMed ID: 10146982 [No Abstract] [Full Text] [Related]
7. MaLAM, a medical lobby for appropriate marketing of pharmaceuticals. Mansfield PR Med J Aust; 1997 Dec 1-15; 167(11-12):590-2. PubMed ID: 9418797 [No Abstract] [Full Text] [Related]
12. The political economy of pharmaceutical marketing channels: a conceptual framework. Doucette WR; Schommer JC; Wiederholt JB Clin Ther; 1993; 15(4):739-51. PubMed ID: 8221824 [TBL] [Abstract][Full Text] [Related]
13. Synthesizing evidence from multiple studies. The role of meta-analysis in pharmacoeconomics. Lafata JE; Koch GG; Ward RE Med Care; 1996 Dec; 34(12 Suppl):DS136-45. PubMed ID: 8969322 [No Abstract] [Full Text] [Related]
14. Pharmacists' and physicians' attitudes toward pharmaceutical marketing practices. Poirier TI; Giannetti V; Giudici RA Am J Hosp Pharm; 1994 Feb; 51(3):378-81. PubMed ID: 8160692 [No Abstract] [Full Text] [Related]
15. Working toward a common currency: is standardization of cost-effectiveness analysis possible? Luce BR J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S19-22. PubMed ID: 7493194 [TBL] [Abstract][Full Text] [Related]
16. Researching the market: initial steps in designing a marketing program. Tootelian DH Am Pharm; 1990 Jan; NS30(1):23-8. PubMed ID: 2301248 [TBL] [Abstract][Full Text] [Related]
17. Is there a need for standardization of methods in economic evaluations of medicine? Rittenhouse BE Med Care; 1996 Dec; 34(12 Suppl):DS13-22. PubMed ID: 8969311 [No Abstract] [Full Text] [Related]
18. Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America. Clemens K; Townsend R; Luscombe F; Mauskopf J; Osterhaus J; Bobula J Pharmacoeconomics; 1995 Aug; 8(2):169-74. PubMed ID: 10155611 [TBL] [Abstract][Full Text] [Related]
19. The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. Glennie JL; Torrance GW; Baladi JF; Berka C; Hubbard E; Menon D; Otten N; Rivière M Pharmacoeconomics; 1999 May; 15(5):459-68. PubMed ID: 10537963 [TBL] [Abstract][Full Text] [Related]
20. Avoiding legal and ethical pitfalls of industry-sponsored research: the co-existence of research, scholarship, and marketing in the pharmaceutical industry. Dorfman HL; Reig LP Food Drug Law J; 2004; 59(4):595-615. PubMed ID: 15880876 [No Abstract] [Full Text] [Related] [Next] [New Search]